bio-life science Company spotlight
Azure8 LLC Company Information
Azure8 LLC provides H-Stat, World’s first primary hemostatic agent that stops major hemorrhages in seconds, without the need for any traditional applications of pressure, elevation, tourniquets or cauterization. H-Stat is effectives in patients who are on anticoagulants therapies (e.g., Coumadin, Heparin) and in patients who are factors deficiencies (Hemophilia patients). H-Stat doesn’t cause adhesion and inflammation post surgeries which results in complications and readmissions. Primary uses are in all surgical procedures including in neuro and ophthalmic where there are currently very limited options to avoid hemorrhages which could mean the difference between life and death. The H-Stat hemostatic agent is CE marked approved as a Class 3 medical device, with over 10 SKU’s – solution for surgical application, spray for burn patients and accidental situations and foam especially designed for our troops in combat zone. H-Stat has completed Phase 1 and 2 clinical testing and will start Phase 3 testing in mid-2019. In 2016, the global hemostats market was $2.7 billion and is expected to reach $8.3 billion by 2024. North America has largest market share at 57.7%. Management team strengths include extensive experience in global new product launches, R&D, manufacturing and operations and managing global distribution networks, and clinical and regulatory expertise. Within five years after market release, the management team expects to achieve total sales revenue from manufacturing of $1.7+ billion at operating margins of about 91%, creating multiple opportunities for an acquisition yielding high ROIs for investors.
About Vipula Tailor, CEO
Vipula Tailor is an experienced pharma executive and entrepreneur with over 18 years of international business development, licensing, R&D and commercialization. Her expertise includes biotech, pharmaceuticals, medical devices/diagnostics, and healthcare. She also has expertise in strategic and operational aspects of drug discovery and development, and in forging successful, synergistic partnerships worldwide
High Growth Companies
Abilis Life Sciences, Maryland
Abilis Life Sciences, Maryland
Abilis Life Sciences, Maryland
Barry Cohen, CEO
Abilis Life Sciences, Inc. (“Take pain out of bladder cancer”) provides a non-invasive bladder cancer test to accurately “rule in or rule out” bladder cancer for initial detection and monitoring of recurrence. Less than 5% of persons currently assessed for bladder cancer using invasive and costly urinary biomarker and other standard tests actually have cancer. By contrast, the company’s bladder cancer test has a 95% accuracy in detecting cancers and 80% accuracy in ruling out non-cancer cases. Primary purchasers are urologists, PCP's and health insurance payers. Once approved for use, the company expects about 1.5 million testing opportunities annually (projected revenues of $100 million). Management team strengths include extensive experience in IT and engineering management, business operations, launching new cancer diagnostics tests, and developing and successfully licensing medical technologies. Support team strengths include extensive experience in development of urology devices, professional medical practice (e.g., VA Medical Center, Baltimore, University of Chicago) and expertise in urologic oncology. The company is now pre-revenue and working on key milestones (e.g., FDA approval, AUA medical guidelines and CMS reimbursement coverage). The management team is also planning to identify and secure a use-test partner such as a major diagnostics company or a national laboratory, and expects to achieve a significant company valuation after completing milestones and market entry.
Medley Genomics, Delaware
Abilis Life Sciences, Maryland
Abilis Life Sciences, Maryland
Patrice Milos, CEO
Medley Genomics (“Patient Hope for Lasting Cures”) provides a software platform that uses patent-pending algorithms and advanced data analytics to describe a patient's diverse tumor cell mixture. This enables creation of unique, patient specific, molecular diagnostic fingerprints for improving identification, diagnosis and treatment of cancer, and helps to improve novel oncology therapies such as personalized cancer vaccine development. Cancer, a heterogeneous disease, has significant tumor cell variability within individual patients, as well as across categories of patients, creating complex barriers to effective and lasting treatment. In 2017, 1.7 million people in the US were diagnosed with cancer, and even though cancer survival rates have increased, it accounts for 1 in 4 deaths annually, often as a result of cancer relapse. Primary purchasers are translational oncology clinical development and pharmaceutical discovery organizations and personalized oncology vaccine companies. Company offerings include software licenses or services. Management team strengths include extensive executive-level experience in business including pharma and biotech, successful software company partnerships, extensive bio-health industry contacts, and expertise in computational solutions for cancer genomics. Support team strengths include extensive experience in venture investment (Life Sciences-Slater Technology Fund), expertise in genomic software/informatics and sequencing technology, and launch of startup companies. The company is now planning to develop clinical/cost-benefit metrics and secure revenue-generating partnerships with 10-15 pharmaceutical companies. Expected results are significantly increased company valuations within 18-36 months and offer attractive acquisition opportunities.
Xooker, LLC, Kentucky
Abilis Life Sciences, Maryland
Xooker, LLC, Kentucky
Conrad Carney, CEO
Xooker (“Play - Earn – Save”) is a “hyper-local” mobile advertising and rewards platform that incorporates gamification (mobile arcade like games), on a single platform for small and medium-sized businesses to help them attract, acquire, engage, and reward customers via their mobile devices. To gain access to merchant benefits and loyalty incentives, customers download the engaging, all-in-one, game-based platform offering a suite of mobile and digital services. Merchants then send Geo-targeted ads, brand highlights, rewards, incentives and other information that match individual customer interests. Results are profitable repeat business and an end to “one-size-fits-all” discounts. Primary purchasers are small and medium-sized businesses that rarely, or never, use mobile in their advertising (nearly 85%-90% of all U.S. businesses). The total estimated market opportunity is currently $28.3 billion, growing at about 71%+ CAGR. The company’s marketing strategy focuses intensively on mid-level communities and execution of exclusive partnerships that enable rapid customer acquisition and local market domination. Management team strengths include extensive experience in the mobile industry, company exits (one IPO), reward and loyalty programs, and executing national and international market strategies. Support Team strengths include extensive experience in business development, sales and marketing, hedge fund management and professional legal expertise. The company, already a national growth leader in mobile loyalty and rewards marketing, expects to achieve $2 million in annualized revenue within the next six months in its first three markets and create a significant investor ROI opportunity.